SavedAdd your journal

Journals / Retina-Vitreus / 2011 / Cilt: 19 - Sayı: 1

The efficasity of intravitreal bevacizumab injection for macular edema due to retinal vein occlusion

Retinal ven tıkanıklığına bağlı maküla ödemi tedavisinde intravitreal bevacizumab enjeksiyonunun etkinliği

Utku LİMON
Erdinç CEYLAN
Barış YENİAD
Koray AKARÇAY
Nur KIR
Tunç OVALI
Pages
27–31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The efficiency decreased after 1 months.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate visual acuity and foveal thickness alterations after intravitreal bevacizumab injection for macular edema due to retinal vein occlusion.
📊
Key Findings & Data:Material and Methods: Twenty-two eyes of 22 patients who underwent intravitreal bevacizumab injection for macular edema due to retinal vein occlusion were retrospectively analyzed.
💡
Conclusion & Impact:The efficiency decreased after 1 months.
🔬Design:Experimental Field Trial
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate visual acuity and foveal thickness alterations after intravitreal bevacizumab injection for macular edema due to retinal vein occlusion. Material and Methods: Twenty-two eyes of 22 patients who underwent intravitreal bevacizumab injection for macular edema due to retinal vein occlusion were retrospectively analyzed. Single doze (1.25 mg/0.05 ml) bevacizumab (Avastin, Altuzan, Genantech,) injection was performed in every patient. Best corrected visual acuity (BCVA) and foveal thickness with OCT were evaluated before and 1, 3, 6 months after injection. Results: The mean follow-up time was 8.64±2.4 (6-14) months. The mean preinjection BCVA was 1.21±0.41.The mean BCVA 1, 3 and 6 months after injections were 0.72±0.21, 0.73±0.23, 0.94±0.24, logMAR. respectively.The mean preinjection foveal thickness was 495±125 μm.The mean Foveal thickness 1, 3 and 6 months afterinjections were 279±75 μm, 297±83 μm, 345±91 μm respectively.The improvements in BCVA and foveal thickness at 1 and 3 months after injection were statistically significant compared to preinjection values. Conclusion: the efficiency of single dose iv bevacizumab injection for macular edema due to retinal vein occlusion was maximum at 1 month. The efficiency decreased after 1 months.

Özet

Amaç: Retinal ven tıkanıklığına bağlı maküla ödemi tedavisinde intravitreal bevacizumab enjeksiyonu sonrası görme keskinliği ve fovea kalınlığı değişikliklerini incelemek. Gereç ve Yöntem: Retinal ven tıkanıklığına bağlı maküla ödemi tedavisi için intravitreal bevacizumab (Avastin, Altuzan, Genantech) uygulanan 22 hastanın 22 gözü geriye dönük olarak incelendi. Hastaların her birine bir defa 1.25 mg/0.05 mI bevacizumab enjeksiyonu yapıldı. Enjeksiyon öncesi ve enjeksiyon sonrası 1.ay, 3.ay ve 6.aylarda en iyi düzeltilmiş görme keskinlikleri (EDGK) ve optik koherens tomografi (OKT) ile fovea kalınlık değerleri incelendi. Bulgular: Ortalama takip süresi 8.64±2.4 (6-14) aydı. EDGK, enjeksiyon öncesi 1.21±0.41, enjeksiyon sonrası 1. ayda 0.72±0.21, 3. ayda 0.73±0.23 ve 6. ay da 0.94±0.24, logMAR idi. Ortalama fovea kalınlığı enjeksiyon öncesi 495±125 μm, 1. ayda 279±75 μm, 3. ayda 297±83 μm ve 6. ayda 345±91 μm idi. Birinci ve üçüncü aydaki EDGK’deki ve santral fovea kalınlığındaki düzelmeler enjeksiyon önceki değerlerle karşılaştırıldığında istatistiksel olarak anlamlı bulundu (p=0.001, p=0.013, p=0.001, p=0.012). Sonuç: Retinal ven tıkanıklığına bağlı makula ödemi tedavisinde tek doz intravitreal bevacizumab enjeksiyonu etkinliğinin ilk bir aylık dönemde en yüksek değere ulaştığı görüldü. Bu etkinliğin ilk 1 ay korunduğu ancak ilerleyen takiplerde giderek azaldığı saptandı.

🔖

Cite This Article

LİMON, U., CEYLAN, E., YENİAD, B., AKARÇAY, K., KIR, N., OVALI, T. (2011). The efficasity of intravitreal bevacizumab injection for macular edema due to retinal vein occlusion. Retina-Vitreus, Cilt: 19 - Sayı: 1, 27–31. https://ajindex.com/articles/307710

References (1)

  1. Keleş S, Leçe D, Arslan A, ve ark.: Retinal ven tıkanıklığı ile glob aksiyel uzunluk ilişkisi. Yeni Tıp Derg. 2008;25:205-208 2. Özyol E, Atmaca L. Retina ven tıkanıklığı. T Klin Oftalmol. 2007;66:56-66. 3. Boyd SR, Zachary I, Chakravarthy U, et al.: Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central retinal vein occlusion. Arch Ophthalmol. 2002;120:1644-1645. 4. Costa RA, Jorge R, Calucci D, et al.: Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions:IBeVO Study. Retina. 2007;27:141-149. 5. Stahl A, Agostini H, Hansen LL, et al.: Bevacizumab in retinal ven occlusion-results of prospective case series. Grafes Arch Clin Exp Ophthalmol. 2007;245:1429-1436. 6. Mulcahy MF, Benson AB.: III. Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther. 2005;5:997-1005. 7. Mi In R, Hong K, Ji H, et al.: Effect Of Intravitreal Bevacizumab Injection on Aqueous Humor Cytokine Levels in Clinically Significant Macular Edema. Ophthalmology. 2009;116:80-86. 8. Spandau U, Wickenhauser A,Rensch F,et al.: Intravitreal bevacizumab for branch retinal vein occlusion.Acta Ophthalmol Scand. 2007;85:118-119. 9. Battaglia, Parodi M, Saviano S, Bergamini L, et al.: Grid laser treatment of macular edema in macular branch retinal vein occlusion. Doc. Ophthalmol. 97:427:431. 10. The Central Vein Occlusion Study Group: M.report. Evaluation of grid pattern photocoagülation for macular oedema in central vein occlusion. Ophthalmology. 1995;102:1425-1433. 11. Chen SD, Sundaram V, Lochhead J, et al.: Intravitreal triamsinolone for treatment of iskemik macular edema associated with branch retinal vein occlusion. Am J Ophtalmol. 2006;141:876-883. 12. Karaçorlu M, Karaçorlu S, Özdemir H.: Retina ven tıkanıklığında intravitreal triamsinolon astenoid tedavisi sonrası makülada değişikliklerin incelenmesi. Ret-Vit. 2005;13:273-277. 13. Cahill MT, Kaiser PK, Sears JE, et al.: The effect of arteriovenous sheathotomy on cystoid macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol. 2003;87:1329-1332. 14. Shah GK, Sharma S, Fineman MS, et al.: Arteriovenous adventitial sheathotomy for the treatment of macular edema associated with branch retinal vein occlusion. Am J Ophthalmol. 2000;129: 104-106. 15. Opremcak EM, Rehmar AJ, Ridenour CD, et al.: Radial optic neurotomy for central retinal vein occlusion:117 consecutive cases. Retina. 2006;26:297-305. 16. Rosenfel